Table 1.

Characteristics and outcomes of patients with myocarditis related to COVID-19 vaccine

	Age	Sex	Type of vaccine	Dose	Peak cardiac troponin I (ng/mL)	Peak cardiac troponin T (ng/L)	LVEF (%)	Time to resolution (days)
1	25	M	Moderna	2nd	20.4		55%	3
2	21	F	Moderna	2nd	4.4		50%	1
3	17	M	Pfizer-BioNTech	1st	51.37		53%	6
4	28	M	J&J	NA	17.08		50%	2
5	39	M	Pfizer-BioNTech	2nd	11.01		56%	4
6	39	M	Moderna	2nd	13		52%	3
7	24	M	Pfizer-BioNTech	1st	0.37		48%	2
8	19	M	Pfizer-BioNTech	2nd	4.49		50%	3
9	20	M	Pfizer-BioNTech	2nd	0.48		52%	4
10	23	M	Pfizer-BioNTech	2nd	7		50%	2
11	52	M	Moderna	2nd	6.77		54%	4
12	16	M	Pfizer-BioNTech	2nd		1693	61%	6
13	30	M	Pfizer-BioNTech	2nd	12.56		"normal"	Resolved (duration not reported)
14	24	M	Moderna	2nd	18.94		65%	Resolved (duration not reported)
15	39	M	Pfizer-BioNTech	1st		854	"normal"	6

M = male; F = female; LVEF = left ventricular ejection fraction.